BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $191

Moomoo News45minutes ago · Ratings

AbbVie (ABBV.US) JAK inhibitor "upadacitinib" is proposed for priority review in China.

On December 10, the official website of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration announced that AbbVie (ABBV.US) has applied for the inclusion of upadacitinib sustained-release tablets in priority review, with the intended indication being the treatment of adult giant cell arteritis (GCA).

Zhitong Finance21:03 ET

BofA Restarts Coverage of 11 Large-cap Biopharmas

Seeking Alpha17:01 ET

Market Falls Wednesday, but Googles Chip Impresses | WST

Kevin Travers16:19 ET

AbbVie Treatment of Multiple Myeloma Granted FDA Orphan Designation

TipRanks15:00 ET

Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock

Kevin TraversDec 10 10:51 ET